AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.

@article{Cheung2005AIDSrelatedME,
  title={AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.},
  author={Matthew C Cheung and Liron X Pantanowitz and Bruce J. Dezube},
  journal={The oncologist},
  year={2005},
  volume={10 6},
  pages={
          412-26
        }
}
Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS). Despite the advent of highly active anti-retroviral therapy (HAART), malignancy in this population is a leading cause of morbidity and mortality. Kaposi's sarcoma (KS) and AIDS-related non-Hodgkin's lymphoma (ARL) are the most common AIDS-defining malignancies. AIDS-related KS varies from minimal to fulminant disease… 

Figures from this paper

AIDS-related malignancies: state of the art and therapeutic challenges.

TLDR
Special considerations of these AIDS-related and non-AIDS-related malignancies and their clinical and therapeutic aspects constitute the subject of this review.

Infectious complications of cancer chemotherapy in HIV patients

The outcome for HIV-infected patients with cancer has dramatically improved in the highly active antiretroviral therapy (HAART) era, probably due to improvements in immune status and bone marrow

HIV Infection and Malignancy

TLDR
General management considerations for patients with HIV and a malignancy are reviewed, as well as a discussion of specific malignancies.

The growing problem of non-AIDS-defining malignancies in HIV

TLDR
It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting.

Oncologic Complications of Human Immunodeficiency Virus Infection: Changing Epidemiology, Treatments, and Special Considerations in the Era of Highly Active Antiretroviral Therapy

TLDR
The effectiveness of antineoplastic therapy and its related toxicities should be vigilantly monitored in this patient population because the metabolic pathways of many of these agents are similar.

Non-AIDS defining cancers.

TLDR
In the last decades, in people with HIV/AIDS, non-AIDS-defining cancers (NADC) have been increasing and occur with greater frequency in HIVpositive patients than in the general population, but are not thought to be directly associated with the degree of immunosuppression.

Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.

TLDR
No evidence is found that the systemic interventions for untreated patients with AIDS-related NHL provide superior clinical effectiveness for improving OS, DSF, and tumour response rate; however, this conclusion is based on four RCTs with limited sample size and variable quality.

Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.

TLDR
3 patients who experienced severe vinblastine-associated neurotoxicity during concomitant treatment with ritonavirboosted antiretrovirals are reported and the implications for the treatment of patients with HL in the current era of cART are discussed.

Evolving spectrum and incidence of non-AIDS-defining malignancies

TLDR
Although control of HIV viremia has proven to be beneficial, the impact of HAART on NADC incidence rates and survival is not uniform, and further effort is needed to resolve the direct and indirect effects of HIV on NADc in order to guide effective prevention and treatment strategies of these malignancies.

Does HIV/AIDS have a biological impact on the risk of human papillomavirus-related cancers?

  • H. Strickler
  • Medicine
    Journal of the National Cancer Institute
  • 2009
TLDR
The risks for both Kaposi’s sarcoma and non-Hodgkin lymphoma were increased by at least 100-fold in persons who developed AIDS compared with the general population, and there were indications of a biological gradient—one of several criteria used to assess a possible causal relationship.
...

References

SHOWING 1-10 OF 185 REFERENCES

Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment.

TLDR
With increasing recognition that effective antiretroviral regimens are associated with both a decreased proportion of new AIDS-defining KS cases and a regression in the size and number of existing KS lesions, most, if not all, patients with KS should be advised to take antireTroviral drugs that will maximally decrease HIV-1 RNA levels.

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.

  • L. RatnerJ. Lee D. Straus
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
Either modified-dose or full-dose CHOP chemotherapy for HIV-NHL, delivered with HAART, is effective and tolerable.

Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.

  • J. StebbingB. Gazzard M. Bower
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Effective HAART-induced maintenance of CD4 and CD8 counts protects from systemic AIDS-related NHL.

Epidemiology of AIDS-related malignancies an international perspective.

Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

TLDR
The results suggest that the improved immune function associated with highly active antiretroviral therapy (HAART) may have led to a shift in pathogenesis away from lymphomas of post-germinal center origin, which have a poor prognosis.

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.

  • Johnson
  • Medicine
    Journal of the National Cancer Institute
  • 2000
TLDR
Since the widespread use of HAART, there have been substantial reductions in the incidence Kaposi's sarcoma and non-Hodgkin's lymphoma in HIV-infected people but, so far, no substantial change in the occurrence of other cancers.

Hodgkin's disease in HIV.

...